文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

单核细胞特征与脑损伤后单纯疱疹病毒再激活及神经功能恢复相关

Monocyte Signature Associated with Herpes Simplex Virus Reactivation and Neurological Recovery after Brain Injury.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论严重脑损伤患者肺内HSV再激活与6个月神经功能恢复差独立相关(HR 1.90),单核细胞特征可预测结局。

研究在344例需有创机械通气的严重脑损伤患者中,系统检测气管抽吸物中的呼吸道HSV复制,并对外周血单核细胞和CD4 T细胞进行染色质免疫沉淀测序、RNA测序及体外功能试验。232例HSV血清阳性患者中39%出现肺部HSV再激活,其与6个月不良神经功能恢复独立相关(HR 1.90;95%CI 1.08–3.57)。单核细胞转录组分析定义了一个包含721个基因(含PD-L1和CD80)的模块,该特征在验证队列中保留,并以良好准确性预测6个月神经功能结局(AUC 0.786;95%CI 0.593–0.978)。作者认为疱疹病毒复制免疫控制改变是未被充分研究的新治疗靶点。

要点

  • 344例严重脑损伤需有创机械通气患者中,232例HSV血清阳性者39%出现肺部HSV再激活。
  • 肺部HSV再激活与6个月不良神经功能恢复独立相关(HR 1.90;95%CI 1.08–3.57)。
  • 单核细胞转录组特征(721基因模块,含PD-L1和CD80)在验证队列中保留,预测6个月神经结局AUC 0.786(95%CI 0.593–0.978)。
  • 该模块富集转录因子Zeb2结合DNA基序,并显示IFN-γ介导和抗病毒反应信号通路降低。

适用人群与场景

  • 严重脑损伤需有创机械通气的患者,来自前瞻性队列,HSV血清阳性者232例纳入HSV再激活分析。

研究设计与关键结果

  • 研究类型为前瞻性队列(含验证队列),纳入344例严重脑损伤需有创机械通气患者,系统检测气管抽吸物中呼吸道HSV复制。
  • 232例HSV血清阳性患者中39%观察到肺部HSV再激活,与6个月不良神经功能恢复独立相关(HR 1.90;95%CI 1.08–3.57)。
  • 单核细胞转录组加权基因共表达网络分析定义721个基因模块(含PD-L1和CD80),富集转录因子Zeb2结合DNA基序,其本体分析显示IFN-γ介导和抗病毒反应信号通路降低。
  • 该单核细胞特征在验证队列中保留,预测6个月神经功能结局AUC 0.786(95%CI 0.593–0.978)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究(含验证队列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为疱疹病毒复制的免疫控制改变是未被充分研究的新治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Brain injury induces systemic immunosuppression, increasing the risk of viral reactivations and altering neurological recovery. Objectives: To determine if systemic immune alterations and lung replication of herpesviridae are associated and can help predict outcomes after brain injury. Methods: We collected peripheral blood mononuclear cells in patients with severe brain injury requiring invasive mechanical ventilation. We systematically searched for respiratory herpes simplex virus (HSV) replications in tracheal aspirates. We also performed chromatin immunoprecipitation sequencing, RNA-sequencing, and in vitro functional assays of monocytes and CD4 T cells collected on Day 1 to characterize the immune response to severe acute brain injury. The primary outcome was the Glasgow Outcome Scale Extended at 6 months. Measurements and Main Results: In 344 patients with severe brain injury, lung HSV reactivations were observed in 39% of the 232 patients seropositive for HSV and independently associated with poor neurological recovery at 6 months (hazard ratio, 1.90; 95% confidence interval, 1.08-3.57). Weighted gene coexpression network analyses of the transcriptomic response of monocytes to brain injury defined a module of 721 genes, including PD-L1 and CD80, enriched for the binding DNA motif of the transcriptional factor Zeb2 and whose ontogenic analyses revealed decreased IFN-γ-mediated and antiviral response signaling pathways. This monocyte signature was preserved in a validation cohort and predicted the neurological outcome at 6 months with good accuracy (area under the curve, 0.786; 95% confidence interval, 0.593-0.978). Conclusions: A specific monocyte signature is associated with HSV reactivation and predicts poor recovery after brain injury. The alterations of the immune control of herpesviridae replication are understudied and represent a novel therapeutic target.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chaumette T, Cinotti R, Mollé A, et al. Monocyte Signature Associated with Herpes Simplex Virus Reactivation and Neurological Recovery after Brain Injury. Am J Respir Crit Care Med. 2022. PMID: 35486851. doi:10.1164/rccm.202110-2324OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。